Connect with us

Cancer

Ovarian cancer vaccine project advances

Published

on

A UK project to develop the world’s first ovarian cancer prevention vaccine is gathering pace.

A new study will see researchers funded by the charity Cancer Research UK initially establish the targets for the vaccine.

They will investigate which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.

If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.

There are around 7,500 new ovarian cancer cases every year in the UK, and it is the 6th most common cancer in women.

There is no current screening programme for the disease and some women with inherited copies of altered genes are at higher risk.

Ovarian cancer risk is up to 65% higher in women with altered BRCA1 genes, and up to 35% higher in women with altered BRCA2 genes, compared to women without these gene alterations.

Currently, women with BRCA1/2 alterations are recommended to have their ovaries removed by the age of 35, which means that they can’t have children in the future, and they experience early menopause.

Director of the Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine at the University of Oxford and lead for the OvarianVax project, Professor Ahmed Ahmed, said: “We need better strategies to prevent ovarian cancer. Currently women with BRCA1/2 mutations, who are at very high risk, are offered surgery which prevents cancer but robs them of the chance to have children afterwards. At the same time, many other cases of ovarian cancer aren’t picked up until they are in a much later stage.

“Teaching the immune system to recognise the very early signs of cancer is a tough challenge. But we now have highly sophisticated tools which give us real insights into how the immune system recognises ovarian cancer.

“OvarianVax could offer the solution to prevent cancer, firstly in women at high risk but also more widely if trials prove successful. Thanks to this funding, our research can take a big step forward towards a viable vaccine for ovarian cancer.”

Previous research by Professor Ahmed and his team at the University of Oxford has found that immune cells from ovarian cancer patients “remember” the tumour.

Building on this research, the scientists will train the immune system to recognise over 100 proteins on the surface of ovarian cancer, known as tumour-associated antigens.

They will find out which of these antigens trigger the immune system to recognise and kill cells which are becoming ovarian cancer.

Tissue samples from the ovaries and fallopian tubes of people with ovarian cancer will be used to recreate the early stages of ovarian cancer in the study.

The researchers will work with patient and public representatives to establish who would be willing to take the vaccine, who could benefit most from it, how it could be administered and how to ensure it is taken up by as many eligible women as possible, if it is successful in future clinical trials.

It will still take many years for the vaccine to reach a point where it is widely available to women at risk of ovarian cancer.

However, this funding is an exciting step towards a world where doctors can prevent ovarian cancer at an early stage, rather than treating it once the disease has already taken hold.

Chief executive of Cancer Research UK, Michelle Mitchell, said: “Projects like OvarianVax are a really important step forward into an exciting future, where cancer is much more preventable. This funding will power crucial discoveries in the lab which will realise our ambitions to improve ovarian cancer survival.

“OvarianVax builds on the exciting developments in vaccine technology during the pandemic. This is one of many projects which we hope will give women longer, better lives, free from the fear of cancer.”

Insight

AI cuts interval breast cancers in Swedish trial

Published

on

An AI tool cut interval breast cancers by 12 per cent in a Swedish screening trial of more than 105,000 women.

The study also found 27 per cent fewer aggressive breast cancers detected at screening when AI was used.

Interval cancers are cancers found between routine screening appointments because they were missed at the original scan. They are often more dangerous and linked to higher death rates than cancers found at screening.

The MASAI trial is described as the first large randomised study to test whether AI can improve mammography screening, which uses low-dose X-rays to examine breast tissue for signs of cancer.

The AI tool, called Transpara Detection and developed by ScreenPoint Medical, supported radiologists in analysing mammography images.

Earlier results from the same trial showed that Transpara Detection increased cancers found by 29 per cent and reduced radiologist workload by 44 per cent compared with standard double-reading, where two radiologists independently review each scan.

The latest findings indicate higher accuracy with AI support. Sensitivity, the ability to detect cancer, was 6.7 percentage points higher in the AI group while specificity, the ability to rule out healthy cases, was maintained. Results were similar across age groups and breast density levels.

Women screened with AI had 16 per cent fewer invasive interval cancers and 21 per cent fewer large interval cancers than those in the standard screening group.

The system also helps doctors assess risk more precisely by subdividing suspicious findings into BI-RADS 4 categories A, B and C. BI-RADS (Breast Imaging Reporting and Data System) is a standardised scale that guides whether a patient needs closer monitoring, further tests or treatment.

Continue Reading

Insight

Study links changing population to low London screening rates

Published

on

London’s shifting population is holding down breast screening uptake, experts have said, with the capital at 62.8 per cent in 2024, below the NHS’s acceptable 70 per cent threshold.

The London Assembly Health Committee recently heard that the capital faces distinct challenges compared with the rest of the country and that these issues must be addressed.

Josephine Ruwende, a cancer screening lead at NHS England, said frequent moves within the rented sector and the cost-of-living crisis pushing people out of London had made it difficult to reach eligible patients, which she described as “population churn”.

She said: “This is people changing addresses and then not updating their GP, this then affects the invitation process because GP details are used to identify individuals who are eligible.

“In boroughs where we have the highest population churn, we see it strongly associated with lower uptake.”

She noted that even in the wealthiest boroughs there can be high levels of movement, with around 40 per cent of residents changing address within a year.

Such areas also tend to have more people who own second homes or spend long periods abroad, making it harder for the NHS to keep contact details up to date.

As a result, screening invitations may be sent to out-of-date addresses or to people who are overseas.

Leeane Graham, advocacy lead at Black Women Rising, which supports women of colour with a cancer diagnosis, said there were cultural barriers, fear and a mistrust of the health service due to previous experience within communities.

She said: “If you’ve never been for a breast screening before, the thought of having a mammogram can be really, really terrifying.”

Helen Dickens, from Breast Cancer Now, said other reasons included a lack of understanding of breast screening, along with concerns about discomfort, trust and practical issues such as travel.

She said: “We have amazing public transport and we feel that we’ve got great accessibility, but we also know that we don’t have screening centres in every borough.

“We know that for some women that barrier of transport and access will still be a really big reason why they’re not attending screenings.”

NHS London launched its first screening campaign last year in response to the figures, aiming to increase detection at an earlier stage.

Continue Reading

Insight

Period blood screening could boost cervical cancer checks

Published

on

Testing period blood for signs of cervical cancer could offer an accurate, convenient screening option for women who avoid clinic appointments, researchers say.

The current NHS test involves a nurse or doctor taking cells from the cervix, yet a third of those invited do not attend.

A study of the new test, which can be done at home, used blood collected on a cotton strip attached to a standard sanitary pad.

In research involving more than 3,000 women aged 20 to 54 years, Chinese investigators compared testing period blood collected on mini-pads with samples taken by clinicians.

Results were shared via a dedicated app.

When analysed in the lab, blood testing was nearly as good at identifying people with disease as other methods, and very good at ruling out those without it.

Cervical screening appointments are offered to all women, and anyone with a cervix, every five years between ages 25 and 64 in the UK.

Screening looks for high-risk human papillomavirus, a virus that can cause cancer.

A nurse or doctor carries out the test using a speculum to access the cervix.

However, five million women are not up to date, for reasons including fear, pain and discomfort.

“Cervical screening can be difficult for some women for many reasons, like if they have had a bad previous experience, they are menopausal, they have a physical or learning disability, cultural barriers, or are a survivor of sexual violence,” said Athena Lamnisos from charity The Eve Appeal.

Younger women, those with disabilities, and people from ethnic minority communities and LGBT+ groups are more likely to miss appointments.

Researchers say using menstrual blood for HPV testing is convenient, respects privacy and reduces discomfort.

Anyone who tests positive for HPV would be sent for a colposcopy, a close examination of the cervix with a magnifying instrument to look for pre-cancerous cells.

Experts caution that period blood tests are not an immediate alternative to current screening because only women who menstruate could use them.

Some also note the study may have overestimated performance because not all participants had a biopsy to double check results.

Sophie Brooks, health information manager at Cancer Research UK, said it was encouraging to see research exploring new ways to make screening more accessible.

She said testing menstrual blood for HPV was an interesting, non-invasive approach but more research in diverse groups is needed to see how it could fit into existing programmes.

Athena Lamnisos added that it was exciting to see more acceptable ways of offering a potentially life-saving test.

“People have different barriers and concerns about screening, so being able to offer a choice of different methods could be very positive for some who are eligible for screening but don’t currently attend,” she said.

The NHS is already sending at-home test kits to women in some areas of England who have missed several screening appointments.

These DIY kits, containing a vaginal swab, will be sent out more widely at some point this year.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.